Skip to main content
logo
HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,890.00
+40.00 (0.51%)
Aug 24, 2026, 9:12 AM KST

HLB Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2019FY 2018FY 2017
Period EndingJun '26 Dec '25 Dec '24 Dec '19 Dec '18 Dec '17
Revenue
251,946205,582137,08236,10020,54115,558
Revenue Growth
68.61%49.97%279.73%75.75%32.03%-
Gross Profit
116,163106,41686,52618,0424,4652,760
Operating Income
1,8701,0641,4741,441-5,826-3,853
Net Income
2,7574,5722,020472.66-7,060-5,447
Earnings Per Share
83.23140.0063.0034.13-521.49-455.00
EPS Growth
-51.94%122.22%84.58%---

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2019FY 2018FY 2017
Period EndingJun '26 Dec '25 Dec '24 Dec '19 Dec '18 Dec '17
Cash & Investments
19,18422,13721,99215,1639,10711,389
Total Debt
19,99020,68416,05513,1987,69414,953
Net Cash (Debt)
-806.131,4535,9381,9651,413-3,564
Net Cash Growth
--75.53%202.18%39.05%--
Net Cash Per Share
-24.2944.45185.20141.88104.39-297.72

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2019FY 2018FY 2017
Period EndingJun '26 Dec '25 Dec '24 Dec '19 Dec '18 Dec '17
Operating Cash Flow
4,328568.986,8411,353-1,777-784.3
Capital Expenditures
-8,617-7,210-2,799-1,397-1,095-2,236
Free Cash Flow
-4,290-6,6424,042-43.8-2,872-3,020
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2019FY 2018FY 2017
Period EndingJun '26 Dec '25 Dec '24 Dec '19 Dec '18 Dec '17
Gross Margin
46.11%51.76%63.12%49.98%21.74%17.74%
Operating Margin
0.74%0.52%1.07%3.99%-28.37%-24.77%
Pretax Margin
1.19%2.43%0.85%-0.34%-27.84%-35.76%
Profit Margin
1.09%2.22%1.47%1.31%-34.37%-35.01%
FCF Margin
-1.70%-3.23%2.95%-0.12%-13.98%-19.41%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2019FY 2018FY 2017
Period EndingAug '26 Dec '25 Dec '24 Dec '19 Dec '18 Dec '17
PE Ratio
94.3249.27167.55159.09--
P/FCF Ratio
--83.73---
PS Ratio
0.441.102.472.082.855.16